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of Biology, University of New Mexico, Albuquerque, New MexicoABSTRACT We use ﬂow cytometry to characterize equilibrium binding of a ﬂuorophore-labeled trivalent model antigen to biva-
lent IgE-FceRI complexes on RBL cells. We ﬁnd that ﬂow cytometric measurements are consistent with an equilibrium model for
ligand-receptor binding in which binding sites are assumed to be equivalent and ligand-induced receptor aggregates are
assumed to be acyclic. However, this model predicts extensive receptor aggregation at antigen concentrations that yield strong
cellular secretory responses, which is inconsistent with the expectation that large receptor aggregates should inhibit such
responses. To investigate possible explanations for this discrepancy, we evaluate four rule-basedmodels for interaction of a triva-
lent ligand with a bivalent cell-surface receptor that relax simplifying assumptions of the equilibrium model. These models are
simulated using a rule-based kinetic Monte Carlo approach to investigate the kinetics of ligand-induced receptor aggregation
and to study how the kinetics and equilibria of ligand-receptor interaction are affected by steric constraints on receptor aggregate
conﬁgurations and by the formation of cyclic receptor aggregates. The results suggest that formation of linear chains of cyclic
receptor dimers may be important for generating secretory signals. Steric effects that limit receptor aggregation and transient
formation of small receptor aggregates may also be important.INTRODUCTIONAntigen recognition by mast cells is mediated by antigen-
specific IgE antibody bound to FceRI (1), a multimeric cell-
surface receptor that binds IgE in a 1:1 ratiowith a high avidity
and a long lifetime (2,3). Interaction of a multivalent antigen
with IgE-FceRI complexes results in clustering of FceRI,
which initiates an intracellular signaling cascade that leads
to the rapid release of histamine and other mediators of
allergic reactions stored in cytoplasmic granules as well as
the synthesis and secretion of yet other mediators (4).
Various reagents have been used to induce clustering of
FceRI (or IgE-FceRI), including chemically crosslinked olig-
omers of IgE (5,6), monoclonal IgE- and FceRI-specific anti-
bodies (7–10), haptenated carrier molecules (11,12), and
chemically synthesized antigens with either two or three
identical hapten groups recognized by monoclonal anti-
hapten IgE (13–18). Studies with these reagents have re-
vealed that signaling and cellular responses can depend
strongly on the properties of FceRI aggregates (19).
Antigen valence is one factor that can affect cellular
responses to antigen-induced aggregation of IgE-FceRI
complexes (6,19). Posner et al. (16) reported the synthesis
of a trivalent antigen that elicits a potent cellular secretory
response. However, a structurally similar bivalent antigen
was observed not to elicit detectable levels of secretion. In
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0006-3495/10/01/0048/9 $2.00of fluorophore-labeled bivalent and trivalent antigens and
demonstrated, as in the study of Posner et al. (16), that the
trivalent antigens are potent secretogues, whereas their biva-
lent analogs fail to stimulate detectable cellular secretory
responses. A variety of evidence suggests that bivalent anti-
gens are poor secretogues because they tend to aggregate
receptors in the form of cyclic dimers, which produce weak
or even inhibitory signals, or to bind the two antigen-
combining sites of a single IgE molecule in cases where the
antigen is sufficiently flexible and large enough to span the
distance between the two antigen-combining sites of an IgE
antibody (15,19–22).
Here, to investigate clustering of IgE-FceRI complexes
induced by trivalent antigens, which evidently differs in
a functionally significant way from the clustering induced
by bivalent analogs, we use flow cytometry to monitor equi-
librium binding of fluorophore-labeled antigen to IgE-FceRI
complexes on rat basophilic leukemia (RBL) cells. The
antigen, which is referred to as compound 6a by Posner
et al. (17), is a synthesized Alexa-488-labeled compound
with flexible glycol linkers connecting three symmetrically
arrayed hapten groups, allowing it to be recognized by
monoclonal anti-hapten IgE. We attempt to explain the
flow cytometric binding data in terms of various mathemat-
ical models for the interaction of a trivalent ligand with
a bivalent cell-surface receptor.
One of the ligand-receptor interaction models that we
consider is the equilibrium continuum model of Goldstein
and Perelson (23), which accounts for all possible acyclic
aggregates that can be formed through the interaction ofdoi: 10.1016/j.bpj.2009.09.043
Steric Effects on Receptor Aggregation 49a ligand with three identical sites and a cell-surface receptor
with two identical sites. The model predicts that a gel or
superaggregate containing large numbers of receptors can
form on the cell surface under certain circumstances.
Other models that we consider are kinetic models related
to the Goldstein-Perelson model that track finite-sized popu-
lations of molecules. These models are formulated using
a rule-based modeling approach (24), which enables us to
relax assumptions of the Goldstein-Perelson model. With
this approach, we can formulate models that account for
the kinetics of ligand-receptor interaction, cyclic receptor
aggregates, and steric constraints on the configurations of
receptor aggregates, which we can expect to be especially
important for large aggregates. The first kinetic model that
we consider is the so-called trivalent ligand-bivalent receptor
(TLBR) model (25) and, like the Goldstein-Perelson model,
is based on the equivalent-site hypothesis (26). This hypoth-
esis states that ligand-receptor interactions are essentially
independent of the molecular context in which they take
place. The two models, for the same equilibrium parameters,
yield results that converge in the continuum limit. The re-
maining models, which will be referred to as Models I–III,
are extensions of the TLBR model that account for cyclic
receptor aggregates and/or steric constraints on aggregate
configurations. Other types of steric constraints have been
considered in earlier work (27–30). Here, we will only be
concerned with constraints on the spatial arrangement of
molecules within molecular complexes. Likewise, we will
not consider spatial effects arising from diffusion.
The rule-based modeling approach is based on the idea of
using graphs to represent molecules and graph-rewriting
rules to represent molecular interactions (24,31,32). A rule
can be viewed as an implicit definition of a class of reactions,
a set of reactions all involving a common transformation. The
rules of a model specification often imply a large-scale chem-
ical reaction network, which is the case for all of the rule-
based models that we consider here. In fact, the networks
implied by the rules of the TLBR model and Models I–III
are so large that simulation of these models using conven-
tional methods is impossible (24,25). Recently, this problem
has been overcome by the development of kinetic Monte
Carlo methods specifically designed for rule-based models
(25,33,34). Here, we show how the method of Yang et al.
(25) can be used to account for geometric constraints on
the formation of molecular complexes.
The results of our model-based analysis of ligand-receptor
binding data suggest that factors that limit the size of ligand-
induced receptor aggregates, perhaps only transiently,
explain why compound 6a is a potent secretogue. It seems
likely that this ligand induces linear chains of cyclic dimers;
however, no definitive conclusions can be drawn at this time.
We also delineate how various steric constraints on ligand-
induced receptor aggregate configurations generally affect
multivalent ligand-receptor binding and gelation, extending
earlier studies of gels on cell membranes (23,35–37).MODELS
We assume that a trivalent ligand interacts with a bivalent
cell-surface receptor in a well-mixed system. The three
binding sites of the ligand are assumed to be identical, as
are the two binding sites of the receptor. Due to the multiva-
lent nature of the ligand and receptor, the number of distinct
ligand-induced receptor aggregates that can form is very
large (23–25). Among the different possible structures of
receptor aggregates are chains, trees, and cyclic aggregates
(see Fig. S1 of the Supporting Material). We assume that
the ligand is such that it cannot bind both sites of a receptor
at the same time.
We will consider five different models for the system
described above, two of which have been formulated in
earlier work. These models are the equilibrium continuum
model of Goldstein and Perelson (23) and a kinetic version
of this model (known as the TLBR model (25)). Both models
are based on the equivalent-site hypothesis (26). We intro-
duce three kinetic models, which account for steric
constraints on configurations of receptor aggregates: a model
allowing for formation of linear chains of cyclic receptor
dimers, which we will refer to as Model I; and two models
in which aggregates form on a hexagonal lattice, which we
will refer to as Models II and III, respectively. Models I–
III describe the formation of planar receptor aggregates
anchored to the cell surface. Model II includes only acyclic
receptor aggregates, whereas Models I and III consider
cycles of two and six receptors, respectively. Model II is
a special case of Model III.Goldstein-Perelson model
The Goldstein-Perelson model (23) is based on the assump-
tion of thermal equilibrium. Interactions between ligands
and receptors include only two types of associative binding
reactions: binding of a site on a free ligand to a site on
a cell-surface receptor, and crosslinking of two receptors by
a ligand. These interactions are characterized by the following
dimensionless parameters,
c ¼ 3K1CNL; (1)
b ¼ K2CR; (2)
where the equilibrium association constant K1 characterizes
the binding of a ligand site in solution to a receptor site,
the equilibrium crosslinking constant K2 characterizes the
binding of a tethered ligand site to a receptor site, CN
L is
the concentration of free ligand in solution at equilibrium,
and CR is the total concentration of receptors. Note that
a linear chain elongation reaction is assumed to be character-
ized by the same crosslinking constant K2 as a reaction that
forms a branch.
The Goldstein-Perelson model accounts for all possible
receptor aggregates except cyclic aggregates. A key elementBiophysical Journal 98(1) 48–56
FIGURE 1 Reaction scheme of trivalent ligand-bivalent receptor interac-
tions. Missing or variable parts of complexes are indicated by dotted lines.
(a) A ligand from solution is captured by a cell-surface receptor with single-
site rate constant kþ1. (b) A tethered ligand crosslinks two receptors with
single-site rate constant kþ2. (c) Scheme of the dimer closure reaction.A factor
of 2 before the single-site dimer closure rate constant jþ2 indicates that there are
two open ligand sites that a receptor can bind. Four bonds can break in a disso-
ciation reaction. (d) InModel III, a hexagonal receptor aggregate can formwith
rate constant jþ6 when free ligand and receptor sites belonging to the same
aggregate are positioned next to each other. In all cases, dissociation is
a context-independent reaction that occurs with single-site rate constant koff.
50 Monine et al.of this model is a partition function, which is a sum of the
concentrations of all possible linear and branched aggregates.
The partition function can be used to obtain expressions for
CN
L and the fraction of free (unbound) receptors, x (see the
Supporting Material).
The model predicts the fraction of receptors in a gel, fg (a
large cluster of receptors connected by ligand-receptor bonds),
which is given by
fg ¼ 1 ð1 þ cÞ
b
h
1 þ ð1 þ 1=cÞ1=2
i
: (3)
Equation 3with fg¼ 0 describes the boundary of a percolation
transition in the space of the parametersb and c. In the absence
of a gel, the system contains free ligands, unaggregated
cell-surface receptors, and small ligand-induced receptor
aggregates.
TLBR model
The TLBR model is a kinetic version of the Goldstein-Perel-
son model formulated in terms of rules for ligand-receptor
interactions (25). As indicated by the rules illustrated in
Fig. 1, a and b, binding of a ligand from solution to a cell
surface-receptor takes place with single-site forward rate
constant kþ1, and crosslinking of receptors occurs with
single-site rate constant kþ2. All association reactions are
reversible, and dissociation occurs with single-site rate
constant koff.
The rules of the TLBR model can be specified using
pseudo BioNetGen language (31) as















LðrÞ þ RðlÞ; (6)
where L denotes a ligand, R denotes a receptor, r denotes one
of the three identical binding sites on a ligand, and l denotes
one of the two identical binding sites on a receptor. The plus-
symbol (þ) on the left-hand side of Eqs. 4 and 5 indicates
that reacting sites must be members of distinct chemical
species, i.e., a reaction implied by one of these rules has mo-
lecularity 2. The period (.) indicates that molecules are
members of the same complex. The above rules represent
capture of free ligand (Eq. 4), receptor crosslinking (Eq.
5), and ligand-receptor dissociation (Eq. 6). Reaction rate
constants associated with these rules are single-site rate
constants, kþ1, kþ2, and koff, respectively. Note that the
rule given by Eq. 5 states that a crosslinking reaction occurs
if at least one site r on a ligand L is already bound to
a receptor, which is indicated by the rþ notation. The super-
scripts in Eqs. 4–6 indicate bonds; sites that share a common
superscript are understood to be connected by a (noncova-
lent) bond.Biophysical Journal 98(1) 48–56Models with steric constraints
In the TLBR model, spatial configurations of receptors in
aggregates are assumed to be unimportant. In contrast, in
Models I–III, the rates of association reactions are assumed
to depend on the configurations of receptors in aggregates.
Models I–III involve rules with application conditions that
specify constraints on receptor aggregate configurations. In
Models I–III, all dissociation reactions, including ring-
opening reactions, are characterized by a single-site rate
constant, koff. Ring closure reactions in Models I and III
are characterized by single-site rate constants, jþ2 and jþ6,
respectively.
Model I
In Model I, we extend the TLBR model to include a ring-
closure reaction. The formation of cycles is limited to cycles
involving two receptors and two ligands with opposing
ligand sites either free or occupied by receptors outside the
cycle, as illustrated in Fig. 1 c. The single-site rate constant
Steric Effects on Receptor Aggregation 51for the ring-closure reaction is jþ2. The equilibrium ring-
closure constant is J2 ¼ jþ2/koff.
In addition to the three rules specified for the TLBR model
(Eqs. 4–6), we introduce a new rule for the formation of



















Rðl4; l1Þ:Lðr1; r2Þ:Rðl2; l3Þ:Lðr3; r4Þ: ð7Þ
This rule indicates that formation of a cyclic structure is an
intramolecular reaction, which occurs with single-site rate
constant jþ2. The term A1 indicates that an application condi-
tion must be satisfied before the rule can be applied. Here, A1
is taken to mean that Eq. 7 applies only when a reaction
results in a cyclic dimer. We exclude the formation of cyclic
nonplanar aggregates with all ligand and receptor sites being
occupied (38) as well as cycles that contain more than two
receptors. A site of each ligand in a cyclic dimer can be
free so that it can bind another receptor. As a result, larger
aggregates can consist of linear chains of cyclic dimers, as
shown in Fig. S6 a.
Model II
In Model II, we assume that ligands and receptors are rigid
and we treat cell-surface reactions as if they occur on a hexag-
onal lattice, as shown in Fig. S1, b and c, and Fig. S4. To
account for steric constraints on molecular structures of
ligand-receptor aggregates, we track the connectivities and
rotation angles of molecules in aggregates. Once a free
ligand binds a surface receptor, the resulting complex only
has freedom to rotate in two dimensions. Flips in three
dimensions are not allowed. Two binding sites of different
aggregates are not allowed to react if other parts of these
aggregates overlap in space. In other words, steric clashes
are prohibited. Model II is specified by Eq. 6 and the
following rules, which are the same as Eqs. 4 and 5 except
for a rule application condition,




 þ RðlÞ /kþ 2;A2 Lrþ ; r1:Rl1; (9)
where A2 is meant to indicate that these rules do not apply
when a reaction would result in a steric clash. The A2 appli-
cation condition is enforced by tree-traversal search of
graphs representing aggregates to reject events that result
in spatial overlaps.
Model III
Model III accounts for hexagonal cyclic structures. It is an
extension of Model II. The only cyclic structure considered
in Model III contains six receptors, and a single-site rate
constant jþ6 is used to characterize ring-closure reactions
(Fig. 1 d). The rules for this model consists of Eqs. 6, 8, and


























where A3 is an application condition meant to indicate that
the rule only applies for formation of cyclic structures con-
taining six receptors. This application condition is enforced
by a procedure that checks whether ligand and receptor sites
are unbound and positioned next to each other in the same
aggregate.MATERIALS AND METHODS
Reagents
The ligand, a model antigen called compound 6a, was synthesized as
described elsewhere (17). Compound 6a is composed of an Alexa-488 label
and three symmetrically arrayed dinitrophenyl (DNP) groups. The
maximum distance between two DNP groups is estimated to be ~50 A˚ based
on Spartan-AM3 semiempirical calculations (17). This distance is signifi-
cantly smaller than the distance between antigen-combining sites of IgE
(z110–130 A˚) (15,22).
The effective receptor consists of FceRI expressed on RBL cells, tightly
coupled to DNP-specific monoclonal IgE antibody from hybridoma H1
26.82 (39). The average lifetime of an IgE-FceRI complex is >12 h (40),
which is much longer than the timescale of a binding experiment. The mouse
monoclonal anti-DNP IgE coupled to FceRI on RBL cells was isolated from
hybridoma H1 26.82 by affinity purification as described in Holowka and
Metzger (41). Isolation of IgE involved, in the final steps, ion exchange
chromatography, to remove bound DNP-glycine, and gel filtration, to sepa-
rate monomeric IgE from IgE aggregates.
Cells
RBL-2H3 cells (42) were grown adherent in 75 cm2 flasks. Cell cultures,
which were used typically five days after passage, were maintained at
37C. Culture media consisted of MEM 1 with Earle’s salts without gluta-
mine (Gibco BRL, Gaithersburg, MD), 20% fetal bovine serum (HyClone,
Logan, UT), 1% glutamine, 1% v/v penicillin, and 1% v/v streptomycin
(Gibco BRL). To harvest cells, we rinsed and then incubated the cells, for
5 min at 37C, with trypsin-EDTA. Cells harvested for experiments were
washed and resuspended in buffered salt solution (pH 7.7), which was
freshly passed through a 0.22-mm filter. Buffered salt solution consisted of
135 mM NaCl, 5 mM KCl, 1 mM MgCl2 1.8 mM CaCl2, 5.6 mM glucose,
0.1% gelatin, and 20 mM HEPES. Cell suspensions in buffered salt solution
were supplemented with 10 mM sodium azide and 10 mM 2-deoxy-glucose
(Sigma, St. Louis, MO) to inhibit receptor recycling and cellular degranula-
tion during binding experiments. To sensitize cells to DNP, we incubated
cells overnight, while cells were still in culture, with excess (10 mg) anti-
DNP IgE. Cells, which express FceRI (at roughly 300,000 copies per cell
(43)), were exposed to IgE for at least 12 h before harvesting.Flow cytometric binding assays
Binding experiments were performed as described elsewhere (10). Briefly,
we incubated a suspension of sensitized cells, with varying concentrations
of Alexa-488-labeled ligand at room temperature. After incubating for at
least 90 min, we used a FACScan flow cytometer (Becton Dickinson,
Franklin Lakes, NJ), which was controlled with Cell Quest software, to
collect histograms of fluorescence. Flow cytometric data were recorded asBiophysical Journal 98(1) 48–56
ab
FIGURE 2 Fit of the Goldstein-Perelson or the TLBR model to flow cy-
tometric binding data. (a) The y axis indicates the normalized amounts of
ligand bound to cell-surface receptors, l, at different ligand doses. Dots
represent scaled measurements of average cell-associated fluorescence
from the Alexa-488-labeled ligand. (b) Extensive aggregation is predicted
by the TLBR model (solid line) and the Goldstein-Perelson model (dashed
line) for ligand concentrations from 0.2 nM to 30 nM. The model with cyclic
dimers, Model I (dotted line), predicts a sol phase at the same conditions.
Parameter values used to calculate the aggregation curves are listed in Table
1. Other parameter values used in simulations of the kinetic models are koff¼
0.01 s1, NR* ¼ 300, and volume V* ¼ 1012 L. Degranulation data from
Posner et al. (17) are indicated by open dots.
52 Monine et al.the mean fluorescence (520 nm) of the cell suspension. To correct for
nonspecific binding of ligand to cells, we performed a control experiment
using cells lacking surface IgE and subtracted the mean fluorescence
measured in this experiment from that measured in the corresponding exper-
iment with sensitized cells.
Simulation of kinetic models
In the kinetic models, individual molecules and their sites are tracked explic-
itly. A detailed description of the data structures used for this purpose and
the simulation algorithm are presented in the Supporting Material. The soft-
ware used to simulate models is freely available upon request.
The TLBR model accounts for a set of three rule-defined reaction classes
(Eqs. 4–6). These classes are ligand binding, receptor crosslinking, and
dissociation. The reaction rules of Eqs. 4–6 are used in such a way that
any reaction causes exchange of site addresses between lists of reactive sites.
Reactive sites are identified based on the local context of interacting mole-
cules in accordance with the method of Yang et al. (25). The procedure of
next-reaction and reactive-site selection is described in the Supporting Mate-
rial and by Yang et al. (25).
In the models with steric constraints, ligand binding from solution and
receptor crosslinking are treated in the same way as in the TLBR model;
however, final acceptance of reactions depends on a check of the spatial
context of interacting molecules (see Step 2(e) of the simulation algorithm
described in the Supporting Material). If a sampled reaction is not feasible
for steric reasons, the reaction is rejected. To model ligand-receptor interac-
tions on a hexagonal lattice, we use data structures that record the orientation
angles of molecules and their binding sites (Models II and III), as described
in the Supporting Material. To keep track of local configurations that partic-
ipate in intramolecular reactions, we use data structures that record pairs of
open ligand and receptor sites in acyclic dimers (Model I) and hexagonal
open cells (Model III).
In contrast with the Goldstein-Perelson model, which is a continuum
model, the kinetic models account for a finite-sized system. The size of
the simulated system is defined by the total numbers of ligands, NL, and
receptors, NR. The kinetic rate constants kþ1 and kþ2 are related to K1 and
K2 as follows: kþ1 ¼ K1koff/(NAV) and kþ2 ¼ K2koff/(NAV), where V is the
system volume and NA is Avogadro’s number. The relationships between
kþ1, kþ2 and the dimensionless parameters c and b of the continuum model
are given as follows: c ¼ 3kþ1NL,N/koff, and b ¼ kþ2NR/koff, where NL,N
denotes the number of free ligands in solution at equilibrium.
The efficiency of simulating the kinetic models depends on the system
size, and therefore, to make simulations more tractable, we scale parameter
values that are related to the system volume. We specify reference values for
the volume (V*) and the total numbers of receptors and ligands (NR* and
NL*). The kinetic model parameters are scaled such that V ¼ cV*, NR ¼
cNR*, NL ¼ cNL*, kþ1 ¼ c1kþ1*, and kþ2 ¼ c1kþ2*, where c is a volu-
metric scaling factor.TABLE 1 Best-ﬁt values for the equilibrium binding constants
and scaling factor a for the Goldstein-Perelson and TLBR
models and Model I, which accounts for cyclic dimers
Goldstein-Perelson and TLBR* models Model I*
Parameters Estimate Lower limit Upper limit Estimate
K1 (nM
1) 0.467 0.111 0.767 6
K2 (nM
1) 87.03 31.6 128.1 60
a 0.816 0.758 0.881 1
*Reference parameter values used in simulations are V* ¼ 1012 L (40),
NR* ¼ 300 molecules (43), NL* ¼ 4200 molecules, koff ¼ 0.01 s1 (11),
and J2 ¼ 5  103 (20). The values for V*, NR*, and NL* are given for
0.1% of the volume of a cell and a cell density of 106 cells/mL. Confidence
intervals are based on Fig. S2.RESULTS
Analysis of equilibrium binding data
We used flow cytometry to monitor the association of Alexa-
488-labeled ligand with cell-surface receptors at equilibrium
as a function of ligand dose. We then fit the Goldstein-Perel-
son model to the binding data to determine best-fit parameter
values. Fig. 2 a illustrates the agreement between the exper-
imental data and the model fit. The best-fit values for K1 and
K2 (and their 68% confidence intervals) are given in Table 1.
For best-fit parameter values, both the TLBR model and
the Goldstein-Perelson model predict a sol-gel percolation
transition (PT) and extensive receptor aggregation, or forma-Biophysical Journal 98(1) 48–56tion of a gel phase, as ligand concentration increases from
0.2 nM to 30 nM, as shown in Fig. 2 b. The simulated frac-
tion of receptors in the gel phase, fg
s, agrees well with fg,
which is given by Eq. 3. Discrepancy between fg
s and fg
can be attributed to finite-size effects (results not shown).
These effects vanish as c/N.
ab
FIGURE 3 PT modified by finite-size effects and steric constraints. The y
axis in each panel indicates the fraction of receptors in the gel phase. The x
axis in each panel indicates the value of the dimensionless crosslinking rate
constant b. (a) Finite-size effects in the TLBR model and Model II (jþ6 ¼ 0)
depend on the volumetric scaling factor c. Parameter values are scaled by c
as follows: NR ¼ cNR*, NL ¼ cNL*, kþ1 ¼ c1kþ1, and kþ2 ¼ c1kþ2. The
value of fg given by the Goldstein-Perelson model is indicated by the solid
line. Forc¼ 0.1, 1, 10, and100, calculations basedon theTLBRmodel (dotted
lines) andModel II (dashed lines) are shown. TheTLBRmodel approaches the
continuummodel asc/N. (b) Effect of jþ6 on thePTaccording toModel III.
Increase of jþ6 above 100 does not have a significant effect on the PT. In
all calculations, we used the following parameter values: NR* ¼ 300,
NL* ¼ 4200, c ¼ 0.36 (kþ1 ¼ 3  107 molecules1 s1 and NL,Nz NL),
kþ2 ¼ bkoff/ NR* s1, and koff ¼ 0.01 s1.
Steric Effects on Receptor Aggregation 53Fitting of the Goldstein-Perelson or TLBR model to the
experimental data is described in the Supporting Material.
Extensive receptor aggregation is predicted at ligand concen-
trations that yield strong secretory responses (Fig. 2 b). This
finding contradicts studies indicating that extensive receptor
aggregation inhibits secretory responses (4,44,45). We
consider the following possible explanations for this discrep-
ancy:
1. Large receptor aggregates are not inhibitory for the ligand
used here and in Posner et al. (17);
2. Predictions of the Goldstein-Perelson or TLBR model
cannot be trusted because this model is oversimplified
(e.g., it does not account for cyclic aggregate formation
or steric constraints on receptor aggregates); and
3. Large aggregates may be inhibitory, but these aggregates
form late in the response to ligand and the early dynamics
of receptor aggregation play a dominant role in triggering
secretion.
To investigate hypotheses 2 and 3, we study the TLBR
model and Models I–III.
Effect of cyclic receptor dimers
Unbound ligand and receptor sites of an open dimer, like that
shown in Fig. 1 c, are allowed to interact with intramolecular
rate constant jþ2,which has been chosen so that J2¼ jþ2/koff¼
5000, as in Posner et al. (20). In the resulting cyclic structure,
the ligand/receptor ratio is 2:2.
We fit Model I, which accounts for cyclic dimers, to the
equilibrium binding data in the same fashion as before. In
the parameter space of K1 and K2, the region of best fit is
shifted to higher values of K1 z 10
9–1010 M1 (results
not shown). The quality of fit is comparable to that illustrated
in Fig. 2. The best-fit values for K1 and K2 are given in Table
1 (column 5).
As shown in Fig. 2 b, at a ligand concentration that corre-
sponds to extensive receptor aggregation according to the
Goldstein-Perelson model, z0.3 nM, Model I predicts
formation of relatively small clusters. The maximum value
of fg
s predicted by Model I is significantly reduced compared
to that predicted by the Goldstein-Perelson or TLBR model.
Hexagonal lattice constraints
In contrast with the TLBR model, the model with hexagonal
aggregate structures, but without cyclic aggregates (jþ6 ¼ 0)
(i.e., Model II), predicts a gradual change of fg
s as the cross-
linking parameter b is increased, even as the volumetric
scaling factor c goes to infinity, as illustrated in Fig. 3 a.
Receptor aggregation is generally suppressed. When steric
constraints are taken into account, the fraction of receptors
in the gel phase decreases significantly over the considered
range of ligand concentrations (0.01–100 nM).
The possibility for ring-closure reactions (jþ6> 0) changes
the percolation behavior. By including these reactions inModel III (which reduces toModel IIwhen jþ6¼ 0), the effects
of steric constraints are reversed. As shown in Fig. 3 b, an
increase in the value of rate constant jþ6 makes the PT steeper
(i.e., more sensitive to the value of b). As jþ6/N, the PT
occurs at a much lower value of b compared to that in the
TLBR model (~10 times lower), and the transition becomes
steep. The approximate PT boundary simulated using Model
III with jþ6 ¼ 100 s1 is shown in Fig. S5 a. Formation of
stable rings increases the size of the gel region in this phase
plot because each hexagonal cycle in a receptor aggregate
has up to six ligand sites free for receptor crosslinking.
Influence of the ring-closure rate constant, jþ6, on receptor
aggregate structure is illustrated in Fig. 4. The fraction of
receptors in the gel phase, fg
s, as a function of jþ6 at different
system sizes (i.e., at different values ofc), is shown in Fig. 4 a.
A critical range of jþ6 values, in which the PT occurs,Biophysical Journal 98(1) 48–56
ab c
FIGURE 4 Effect of jþ6 on cyclic receptor aggregates in Model III. (a) fg
s
is used as a measure of the aggregate density. At larger system volume (e.g.,
at c¼ 10 vs. c¼ 0.1), the difference in values of fgs whereas jþ6 is varied is
steeper because of finite-size effects. (b and c) Snapshots of simulations
showing two fragments of aggregates: (b) a low-density structure (obtained
with jþ6¼ 0), and (c) a high-density structure (obtained with jþ6¼ 100 s1).
In all calculations, we used the following parameter values: NR* ¼ 300,
NL* ¼ 4200, c ¼ 0.36 (kþ1 ¼ 3  107 molecules1 s1, NL,N z NL),
b ¼ 90 (kþ2 ¼ 3  103 s1), and koff ¼ 0.01 s1.
54 Monine et al.spans 0.1–1 s1. A decrease or increase of jþ6 out of this
range does not cause significant changes. For jþ6 < 0.1,
formation of open cycles (illustrated on the left side of
Fig. 1 d) is the rate-limiting step in aggregation kinetics;
for jþ6 > 1, ring closure stabilizes open cycles once such
aggregates form. Increase of the system size makes the tran-
sition of fg
s more pronounced, but does not influence the
range of sensitivity to jþ6. The value of fg
s can also serve as
a characteristic of the density of aggregates. Fig. 4 b shows
a fragment of a branched aggregate predicted to form in one
particular simulation of Model II (jþ6 ¼ 0, no ring closure).
In contrast, for Model III with jþ6 ¼ 104 s1, cycles are
stable and simulated aggregates have a denser structure char-
acterized by fg
sz 1, as shown in Fig. 4 c.
As shown in Fig. S7, hexagonal lattice constraints can be
effectively captured using an empirical function that charac-
terizes the dependence of binding probability, P(sl, sr), on the
sizes of associating aggregates, sl and sr, and lumped into
factors that multiply binding rate constants.Biophysical Journal 98(1) 48–56Dynamics of aggregation
In our earlier work (25), we found that the TLBR model
predicts that small receptor aggregates form transiently
before the formation of a superaggregate. As seen from the
simulation results of Fig. S8, similar dynamical behavior is
predicted by Model II (jþ6 ¼ 0). Both the TLBR model
and Model II also predict that two ligand doses (0.33 nM
and 8.3 nM), stimulating receptor aggregation to the same
extent at equilibrium (fg z 0.5), can generate qualitatively
distinct time courses of receptor aggregation. A feature of
both models at high ligand concentration (8.3 nM) is an over-
shoot in the average receptor aggregate size (Fig. S9). In
contrast, in Model III with jþ6 >> 0, the transient behavior
changes. As shown in Fig. S9, the overshoot seen in the case
of jþ6 ¼ 0 at high ligand dose disappears.DISCUSSION
Recently, Yang et al. (25) developed a kinetic Monte Carlo
method that can be used to study multivalent ligand-receptor
interactions. Yang et al. (25) also formulated the TLBR
model, a kinetic version of the equilibrium continuum model
of Goldstein and Perelson (23). We have now extended this
model to account for structural properties of the interacting
molecules that place steric constraints on molecular aggre-
gates. We carried out an extensive analysis of steric effects,
considering effects on both equilibrium and kinetic behavior.
As part of our analysis, we analyzed equilibrium binding
data characterizing the interaction of a trivalent antigen,
compound 6a (17), with bivalent IgE-FceRI. To fit these
data to a predictive model and estimate model parameters
describing ligand capture from solution and receptor cross-
linking, we first considered the Goldstein-Perelson model
(23). The model fits the data well (Fig. 2). We found that,
at the best-fit parameter values, the model predicts the forma-
tion of a gel phase for an interval of ligand doses that yield
strong secretory responses (17) (Fig. 2 b). However, this
model prediction contradicts the results of previous studies
that indicate that large aggregates inhibit secretory responses
(4,44,45). The Goldstein-Perelson model, although it fits the
binding data well, is probably oversimplified. It treats sites as
equivalent and does not account for cyclic aggregates or
steric clashes that limit the formation of large aggregates
(Figs. 2–4). It also does not account for the dynamics of
receptor aggregation, which may be important.
We extended the TLBR model (a kinetic version of the
Goldstein-Perelson model) to incorporate formation of cyclic
receptor dimers to obtain Model I. This model accounts for
a cyclic receptor dimer with two opposing ligand sites that
could be occupied to generate linear chains of cyclic receptor
dimers (as illustrated in Fig. S6). Simulation results for this
model are shown in Fig. 2 b. For a fixed value of the ring
closure constant, J2, we adjusted the parameter values K1
and K2 such that a good fit to the equilibrium binding data
Steric Effects on Receptor Aggregation 55was obtained. As expected, the extent of receptor aggrega-
tion is significantly lower in Model I compared to the results
obtained with the Goldstein-Perelson and TLBR models
(Fig. 2 b). In fact, a superaggregate is no longer predicted.
Bivalent antigens similar to compound 6a are believed to
predominantly induce cyclic receptor dimers, but they do
not generate secretory responses. In contrast, crosslinked
cyclic receptor dimers do produce robust secretory responses
(20,21). For these reasons, we believe compound 6a may
induce linear chains of cyclic dimers, which prohibit super-
aggregate formation.
To investigate steric effects due to excluded binding sites
within ligand-induced receptor aggregates, we extended the
TLBR model to track configurations of receptor aggregates
explicitly. The resulting models, Models II and III, are based
on the assumption that ligands and receptors are rigid and
that receptor aggregates form on a hexagonal lattice. In
making this assumption, we consider a case that can be
viewed as opposite to that considered when making the
assumption of equivalent sites. In the TLBR model, which
is based on the equivalent-site hypothesis, there are no steric
constraints on aggregate configurations at all, which corre-
sponds to spacers between binding sites with infinite flexi-
bility. For the ligand considered here (17), the spacers that
connect the DNP groups are not rigid and a considerable
amount of flexibility is possible. The spacers impose
a maximum distance constraint and torsional preferences
can be expected to favor maximum separation of the DNP
groups. However, noncovalent interactions may bias the
ligand toward other, more compact conformations. Note
that the rigidity assumption is more valid for the trivalent
ligands of Sil et al. (18), because the double-stranded DNA
spacers that connect the DNP groups in these ligands are
far more rigid.
Analysis of Model II, in which cyclic structures are not al-
lowed, suggests that steric clashes of parts of interacting
complexes limit aggregation significantly by excluding
binding sites from interactions (Fig. 3 a). However, behavior
of the model changes dramatically if cyclic aggregates are
included (Fig. 3 b). In Model III, cyclic aggregates form
on hexagonal cells. If the rings considered in Model III are
stable (jþ6 >> 0), they essentially turn individual bivalent
receptors into six-valent receptors for ligand. In this case,
ring-closure reactions lead to formation of stable aggregates
of high receptor density (Fig. 4), quite unlike the behavior
predicted by Model I, according to which the density of
aggregates is reduced as a result of ring-closure reactions.
The dynamics predicted by the TLBR model and Model II
are qualitatively similar (compare Fig. S8 of this work and
Fig. 4 of Yang et al. (25)). We hypothesize that early forma-
tion of small aggregates may have a positive effect on secre-
tion. Further growth in aggregate size and reduction in the
number of small aggregates may then have a negative effect
on secretion, consistent with earlier studies reporting inhibi-
tion of secretion by large receptor aggregates (4,44,45). Inthese models, at high rates of ligand capture from solution,
the extent of aggregation passes through a maximum during
the initial time course and then decreases to the equilibrium
level (see Fig. S9). However, when rings are considered (i.e.,
Model II is extended to Model III) and jþ6 >> 0, ring-
closure reactions enhance receptor crosslinking and elimi-
nate overshoot in receptor aggregation, even at high ligand
doses (see Fig. S9).
It should be noted that steric constraints that affect the
interaction of a free receptor site with a free site on a tethered
ligand have been considered in earlier studies (15,27,28).
These constraints, especially those considered by Schweit-
zer-Stenner et al. (15), affect the equilibrium crosslinking
constant and can be accounted for implicitly: the less favor-
able the interaction, the smaller the crosslinking constant.
Similar considerations may be useful for considering more
realistic configurations of receptor aggregates.
The methodology developed here for studying steric
constraints on receptor aggregate configurations can poten-
tially be applied to an array of other problems where the
geometric properties of interacting molecules constrain or
facilitate interactions. The modeling approach may even be
extended to account for the structures of interacting mole-
cules in three-dimensional space.SUPPORTING MATERIAL
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